— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022 , expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal
NEW YORK and DURHAM, N.C. , June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022 . Fiscal Fourth Quarter Financial Summary For the fourth fiscal quarter ended March 31, 2022 , research and development
-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts -Company has engaged SVB Securities to advise it on a range of strategic alternatives to maximize stockholder value -Company had cash and cash equivalents of approximately $64
Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease $81.9 million of cash and cash equivalents as of December 31, 2021 , providing expected cash runway into
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral
– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease, respectively; and to terminate AXO-Lenti-PD license agreement with Oxford Biomedica for Parkinson’s
